KDMN Final Deadline Tomorrow: Rosen, senior litigator, Kadmon Holdings, Inc. encourages losing investors to seek legal counsel ahead of the critical June 2nd deadline in the securities class action – KDMN – Stockhouse

New York, New York – (Newsfile Corp. – June 1, 2021) – WHY: Rosen Law Firm, a global investor rights law firm, is reminding buyers of Kadmon Holdings, Inc. (NASDAQ: KDMN ). , 2020 and March 10, 2021, including (the “Class Period”) the lead plaintiff’s important deadline of June 2, 2021.

SO WHAT: If you purchased Kadmon securities during the class action period, you may be entitled to compensation without paying any out-of-pocket expenses or costs under a contingency fee arrangement.

WHAT TO DO NEXT: To participate in the Kadmon class action lawsuit, visit or call Phillip Kim, Esq. toll free at 866-767-3653 or email [email protected] or [email protected] for class action information. A class action lawsuit has already been filed. If you want to serve as the lead plaintiff, you must call the court no later than June 2, 2021. A lead plaintiff is a representative party who acts on behalf of other class members in the conduct of the dispute.

WHY ROSEN LAW: We encourage investors to select skilled advisors with a track record in leadership roles. Advertising companies often do not have comparable experience or resources. Rosen law firm represents investors around the world and focuses its practice on securities class actions and shareholder derivatives lawsuits. Rosen Law Firm has filed the largest class-action securities lawsuit ever against a Chinese company. Rosen law firm was ranked # 1 by ISS Securities Class Action Services for number of class action settlements in 2017. The firm has been in the top 4 every year since 2013 and has collected hundreds of millions of dollars on investors. In 2019 alone, the company raised over $ 438 million for investors. In 2020, founding partner Laurence Rosen was named Titan of Plaintiffs’ Bar by Law360. Many of the firm’s attorneys are recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, throughout the class, the defendants made false and / or misleading statements and / or failed to disclose that: (1) The new drug application for Belumosudil for the treatment of Chronic Graft-versus-Host Disease (cGVHD ) (the “Belumosudil NDA”) filed with the US Food and Drug Administration (“FDA”) was incomplete and / or defective; (2) the additional new data provided by Kadmon in support of the Belumosudil NDA in response to an FDA request for information materially changed the filing of the Belumosudil NDA; (3) Accordingly, Belumosudil’s original NDA filing lacked the level of support Kadmon had led investors to believe; (4) accordingly, it was likely that the FDA would extend the scheduled date of action of the Prescription Drug Fees Act (“PDUFA”) to review the NDA of belumosudil; and (5) as a result, Defendants’ public statements were, at all relevant times, essentially false and misleading. When the real details hit the market, the lawsuit alleged that investors suffered damage.

To participate in the Kadmon class action lawsuit, visit or call Phillip Kim, Esq. toll free at 866-767-3653 or email [email protected] or [email protected] for class action information.

No class has been certified. Until a class is certified, you will not be represented by a lawyer unless you keep one. You can choose an advisor of your choice. You can also remain an absent class member and do nothing at this point. An investor’s ability to partake in a potential future repayment does not depend on their being the lead plaintiff.

Follow us for updates on LinkedIn:, on Twitter: or on Facebook: https: // www. facebook .com / rosenlawfirm /.

Lawyer advertising. Previous results do not guarantee a similar result.


Contact information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen, PA law firm

275 Madison Avenue, 40th floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

[email protected]

[email protected]

To view the source version of this press release, please visit

Related Articles